Share page on LinkedIn

NASH

Insights from experts on how to best navigate the complexity of NASH clinical trials.

The voice of NASH investigators

The voice of NASH investigators

Global survey provides insights for trial operations

Non-alcoholic steatohepatitis (NASH), a component of metabolic syndrome, is an area of very active clinical development. With no approved therapies to treat NASH, there are more than 130 Phase II or Phase III NASH trials underway or planned.

To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of NASH clinical trial sites across 37 different countries.

Read the whitepaper
Helping NASH study sites to succeed

Helping NASH study sites to succeed

Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s survey of more than 2,000 sites across 30 countries including:

  • How to best support global NASH sites to succeed in a competitive environment
  • Optimising the operational strength of study sites to collectively support the NASH pipeline
  • How understanding global and regional nuances can enhance NASH site patient recruitment and operational strategy
Access the webinar recording
Non-Alcoholic Steatohepatitis (NASH) clinical trials

Non-Alcoholic Steatohepatitis (NASH) clinical trials

Join Andrew Roche, PhD, a senior member of ICON's NASH team, as he speaks about overcoming the challenges and considerations associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.

Access the webinar recording

NASH solutions

Discover more about ICON's solutions in the development and management of all aspects of NASH clinical trials experts.

ICON's services in NASH